74 An evaluation of treatment burden following initiation of TOBI® Podhaler® in patients with CF

Bilton, Diana; Nash, E.F.; Peckham, D.; Haworth, C.S.; Carroll, Mary; Connett, Gary; Udén, Rolf; Oswald, Laura B.; Iorio, Fosca De; Oliver, Gill

doi:10.1016/s1569-1993(14)60210-1

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phase IV studies Several studies (ETOILES, 2403, FREE, FR01, BR01, and GB01) have been conducted to collect real-world data to investigate whether the features of TIP translate into real benefits when used in routine clinical practice as demonstrated in previous studies. 37,50 The results of these real-world studies (ETOILES, 2403, FREE, FR01, and GB01) showed that TIP treatment was associated with lung function benefits and suppression of P. aeruginosa sputum density, which is consistent with the published reports from the phase III trials (Table 3). [43][44][45] The 2403 study also compared the ease of use, device contamination, and safety parameters associated with TIP treatment versus TIS and COLI treatment.…”

Section: Clinical and Microbiologic Efficacy In Phase III Studiessupporting

confidence: 84%

Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence

Hamed

DeBonnett

2017

Ther Adv Respir Dis

View full text Add to dashboard Cite

Chronic airway infection with Pseudomonas aeruginosa is a major cause of increased morbidity and mortality in patients with cystic fibrosis (CF). The development and widespread use of nebulized antibacterial therapies, including tobramycin inhalation solution (TIS), has led to improvements in lung function and quality of life. However, the use of nebulizers is associated with various challenges, including extended administration times and the need for frequent device cleaning and disinfection. Multiple therapies are required for patients with CF, which poses a considerable burden to patients, and adherence to the recommended treatments remains a challenge. Tobramycin inhalation powder (TIP), delivered via the T-326 Inhaler, has been shown to have similar clinical efficacy and safety as compared to TIS, with improved patient convenience, satisfaction, and treatment adherence. Long-term safety studies have shown that TIP was well tolerated with no unexpected adverse events in patients with CF. This review of the TIP pivotal and postmarketing studies reinforces the well-established efficacy and safety profile of TIP and its ease of use.

show abstract

Section: Clinical and Microbiologic Efficacy In Phase III Studiessupporting

confidence: 84%

Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence

Hamed

DeBonnett

2017

Ther Adv Respir Dis

View full text Add to dashboard Cite

show abstract

“…12 It has also been shown to be associated with improved adherence, tolerability and decreased exacerbation rates compared to nebulised treatment in real life practice. 13,14 In contrast and despite its simplicity compared to nebulised colistimethate sodium, prescribing Colobreathe® via the turbospin® (colistimethate sodium inhalation powder, one capsule inhaled twice daily) remains contentious. Colobreathe® is recommended by NICE only if patients would benefit from colistimethate sodium but do not tolerate the nebulised form.…”

Section: Inhaled Antibiotics Therapy: Putting the Patient At The Hearmentioning

confidence: 99%

Lifestyle treatments in cystic fibrosis: The NHS should pay

Ketchell

2016

Paediatric Respiratory Reviews

View full text Add to dashboard Cite

“…Significantly reduced exacerbation rates (measured by the number of intravenous antibiotic courses in 12 months retrospectively during TIS and prospectively during TIP) were also shown, which clearly individuals could not exaggerate. In addition, in a multicentre evaluation of treatment burden following the initiation of TOBI Podhaler and after completion of three treatment cycles, significant improvements in perceived treatment burden, global satisfaction and convenience were observed and sustained at 5 months post-initiation [ 44 ].…”

Section: Treatment Regimens and Adherencementioning

confidence: 99%

Inhaled therapy in cystic fibrosis: agents, devices and regimens

Agent

Parrott

2015

Breathe

View full text Add to dashboard Cite

Key pointsThere have been significant advances in both inhalation medicines and delivery devices with “intelligent nebulisers” and “dry-powder inhalers” becoming commonplace in CF care.Inhaled medicines generate high levels of a drug within the airways with limited systemic effects, offering safe and convenient antibiotic and mucolytic therapy for individuals with CF.Variations in adherence are not unique to CF; however, treatment burden is high and therefore fast inhaled drug delivery devices may assist individuals in completing the prescribed treatment regimes.Prescribers of inhaled medicines have a responsibility to consider, in addition to efficacy, the appropriated drug/device combination for each individual in order to promote adherence and achieve the desired clinical benefit.SummaryThe recognised mainstay daily treatments for cystic fibrosis (CF) focus on inhaled and oral medications, airway clearance and optimised nutrition. This review discusses recent advances in inhaled therapies for the management of CF, including devices such as intelligent nebulisers, drug formulations and supporting evidence for inhaled antibiotics (for the management of chronic Pseudomonas aeruginosa) and muco-active drugs. We include practical advice for clinicians regarding the optimisation of inhalation technique and education. The influence of adherence on the use of inhaled therapies in CF is also reviewed.Educational aimsTo inform readers about the history and progression of inhaled therapies for people with CF with reference to the literature supporting current practice.To highlight the factors that may impact the success of inhaled therapies, including those which are device specific such as drug deposition and those which influence adherence.

show abstract

74 An evaluation of treatment burden following initiation of TOBI® Podhaler® in patients with CF

Cited by 4 publications

References 0 publications

Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence

Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence

Lifestyle treatments in cystic fibrosis: The NHS should pay

Inhaled therapy in cystic fibrosis: agents, devices and regimens

Contact Info

Product

Resources

About